Atazanavir

ARV U.S. Brand Name

Reyataz

ARV Abbreviation(s)

ATV

U.S. FDA Label

Atazanavir Labeling (Package Insert)

ARV Class

Protease Inhibitors

First U.S. Approval

December 19, 2014

U.S. Manufacturer

Bristol Myers Squibb

Formulations

Strength	Formulation	Image	Description	Boosted
150 mg	Capsules	X	Blue and Aqua oblong Capsule with BMS 150 mg, and 3624 imprinted	No
200 mg	Capsules	X	Blue oblong Capsule with BMS 200 mg, and 3631 imprinted	No
300 mg	Capsules	X	Red and Blue Capsule with BMS 300 mg imprinted	No
300 mg of atazanavir and 150 mg of cobicistat	Tablet	X	Oval, biconvex, pink, film-coated, debossed with “3641” on one side and plain on the other side	Yes

Generic Available?

Yes

Other Reference Links

Clinical Info HIV Drug Database (ATV)

National HIV Curriculum (Atazanavir)

Clinical Info HIV Drug Database (ATV/COBI)

National HIV Curriculum (Atazanavir-Cobicistat)

FDCs

Atazanavir / Cobicistat

Displaying 1 - 100 of 140

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Lenacapavir Atazanavir/ritonavir	Red: Avoid combination	Do not coadminister: potentially increased levels of lenacapavir	Potential increase in lenacapavir adverse effects				Use alternative agents
Ritonavir ATV 1036	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of atazanavir	Increased atazanavir effects	Not studied	300 mg daily on days 1-20	Atazanavir AUC increased 238%; Cmax increased 86%; Cmin increased 1089%	Dose atazanavir 300 mg once daily with ritonavir 100 mg daily
Darunavir ATV 906	Green: Administer standard doses	Administer standard doses		No significant change	300 mg once daily	Cmax decrease 11%, AUC increase 8%, Cmin increase 52%
Atazanavir Apixaban 865	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefitsÊof using this combination	Increased apixaban levels, Potential for increased risk of bleeding				Consider using alternative agents
Atazanavir Rivaroxaban 864	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of bleeding				Consider using alternative agents
Atazanavir Voriconazole 863	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential decreased voriconazole antifungal effects		200 mg PO Q12H	Voriconazole AUC decreased 39% when given with ritonavir 100 mg BID	With unboosted atazanavir no dose adjustment necessary, monitor for toxicity. Do not coadminister with boosted protease inhibitors unless benefit outweighs risks. Consider therapeutic drug monitoring.
Atazanavir Fluticasone 862	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Decreased plasma cortisol concentrations (eg, Cushing's syndrome, adrenal suppression)				Use with caution with atazanavir, use with atazanavir / ritonavir is not recommended unless the potential benefit outweighs the risk
Atazanavir Midazolam 861	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased midazolam effects (eg, increased sedation, confusion, respiratory depression)				Parenteral midazolam can be used with caution when given as a single dose in a monitored situation for procedural sedation. Chronic midazolam administration (oral or intravenous) should be avoided.
Atazanavir Quinidine 860	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased quinidine effects (e.g. cardiac arrhythmias)				If coadministering use with caution. Monitor for toxicity.
Atazanavir Propafenone 859	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased propafenone effects (eg, cardiac arrhythmias)				If coadministering use with caution. Monitor for toxicity.
Atazanavir Amiodarone 858	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased amiodarone effects (eg, hypotension, bradycardia, cardiac arrhythmias)				If coadministering use with caution. Monitor for amiodarone toxicity. Consider ECG and amiodarone drug level monitoring.
Atazanavir Lidocaine 857	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination					If coadministering use with caution. Monitor adverse effects and consider therapeutic drug monitoring.
Atazanavir Flecainide 856	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of flecainide adverse effects (eg, cardiac arrhythmias)				If coadministering use with caution and monitor for toxicity. Consider therapeutic drug monitoring
Atazanavir Mexiletine 855	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of mexiletine adverse effects				If coadministering use with caution and monitor for mexiletine toxicity
Atazanavir Disopyramide 854	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of disopyramide adverse effects				If coadministering use with caution and monitor for disopyramide toxicity
Atazanavir Proguanil 853	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potentially compromised antimalarial activity	Not reported	100 mg with 250 mg atovaquone x 1	Proguanil AUC decreased 41%, Cmax no significant change	If coadministering monitor for anti-malarial efficacy
Atazanavir Digoxin 852	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of digoxin toxicity				If coadministering digoxin dose may need to be decreased. Monitor digoxin level and adjust digoxin dose based on clinical signs and drug levels.
Atazanavir Atovaquone 851	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential compromised antimalarial activity	Not reported	250 mg with 100 mg proguanil x 1	Atovaquone AUC decreased 46%, Cmax decreased 49%	Dose adjustment not established. If coadministering monitor for anti-malarial efficacy.
Atazanavir Telithromycin 850	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased telithromycin effects. (e.g. may cause QTc prolongation)				Avoid combination or use alternative agents
Atazanavir Vorapaxar 849	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of bleeding				Use alternative agents
Atazanavir Ticagrelor 848	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of bleeding				Use alternative agents
Atazanavir Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 847	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits					Do not coadminister
Atazanavir Clarithromycin 846	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits					Consider alternative antibiotics
Atazanavir Phenobarbital 845	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential loss of antiretroviral efficacy				Avoid combination or use alternative agents
Atazanavir Phenytoin 844	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential loss of antiretroviral efficacy				Avoid combination or use alternative agents
Atazanavir Apixaban 843	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of bleeding				Avoid combination, use alternative anticoagulant
Atazanavir Erythromycin 842	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits					Avoid combination, use alternative antibiotics
Atazanavir ETR 841	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir and increased levels of etravirine	Potential increased etravirine effects, decreased atazanavir effects	Atazanavir AUC decreased 17%, Cmin decreased 47%		Etravirine AUC increased 50%, Cmax increased 47%, Cmin increased 58%	Use alternative agents
Atazanavir EVG/c 840	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir Cmax decreased 24%, Cmin decreased 20%	Elvitegravir 85 mg daily with cobicistat 150 mg daily	Elvitegravir AUC increased 17%, Cmax decreased 16%, Cmin increased 83%	Use alternative agents
Atazanavir RIF 839	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir AUC no significant change, Cmax decreased 18%, Cmin decreased 40%(compared to atazanavir 400 mg daily)	600 mg daily x 10 d	Not reported	Contraindicated. Use alternative agents.
Atazanavir RIF 838	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir AUC decreased 72%, Cmax decreased 53%, Cmin decreased 98%	600 mg daily x 10 d	Not reported	Contraindicated. Use alternative agents.
Atazanavir RIF 837	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir AUC decreased 57%, Cmax decreased 56%, Cmin decreased 93%(compared to atazanavir 400 mg daily)	600 mg daily x 10 d	Not reported	Contraindicated. Use alternative agents.
Atazanavir RIF 836	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir AUC decreased 31%, Cmax decreased 40%, Cmin decreased 80%(compared to atazanavir 400 mg daily)	600 mg daily x 10 d	Not reported	Contraindicated. Use alternative agents.
Atazanavir CBZ 835	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy				Contraindicated. Use alternative agents.
Atazanavir Phenytoin 834	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiretroviral efficacy				Contraindicated. Use alternative agents.
Atazanavir Phenobarbital 833	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiretroviral efficacy				Contraindicated. Use alternative agents.
Atazanavir St. John's Wort (Hypericum perforatum) 832	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiretroviral efficacy				Contraindicated. Use alternative agents.
Atazanavir Simvastatin 831	Red: Avoid combination	Do not coadminister: Potential for increased levels of simvastatin	Potential Increased simvastatin effects (eg, myopathy, rhabdomyolysis)				Contraindicated. Use alternative agents.
Atazanavir Salmeterol 830	Red: Avoid combination	Do not coadminister: Potential for increased levels of salmeterol	QT prolongation, palpitations, and sinus tachycardia.				Contraindicated. Use alternative agents.
Atazanavir Ranolazine 829	Red: Avoid combination	Do not coadminister: Potential for increased levels of ranolazine	Potential increase in ranolazine adverse effects (e.g. prolonged QT, cardiac arrythmias).				Contraindicated. Use alternative agents.
Atazanavir Quetiapine 828	Red: Avoid combination	Do not coadminister: Potential for increased levels of quentiapine. If coadministration is necessary: reduce dose to 1 / 6 of current dose.	Increased quentiapine effects.				Contraindicated. Use alternative agents.
Atazanavir Pimozide 827	Red: Avoid combination	Do not coadminister: Potential for increased levels of pimozide	Potential increased in pimozide adverse effects (eg, hypotension, cardiac arrhythmias)				Contraindicated. Use alternative agents.
Atazanavir Lurasidone 826	Red: Avoid combination	Do not coadminister: Potential for increased levels of lurasidone	Potential increased in pimozide adverse effects (eg, hypotension, cardiac arrhythmias)				Contraindicated. Use alternative agents.
Atazanavir HMG-CoA Reductase Inhibitors 825	Red: Avoid combination	Do not coadminister: Potential for increased levels of lovastatin	Increased lovastatin effects (eg, myopathy, rhabdomyolysis)				Contraindicated. Use alternative agents.
Atazanavir NVP 824	Red: Avoid combination	Do not coadminister: Potential for increased levels of grazoprevir	May increase risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1 / 3 inhibition		Elbasvir 50 mg daily with grazoprevir 200 mg daily	Elbasvir AUC increased by 4.76-fold, Grazoprevir AUC increased by 10.58-fold	Contraindicated. Use alternative agents.
Atazanavir EBR/GZR 823	Red: Avoid combination	Do not coadminister: Potential for increased levels of grazoprevir	May increase risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1 / 3 inhibition	ATV AUC increased 43% by grazoprevir	Elbasvir 50 mg daily with grazoprevir 200 mg daily	Elbasvir AUC increased by 4.76-fold, Grazoprevir AUC increased by 10.58-fold	Contraindicated. Use alternative agents.
Atazanavir Ergotamine 822	Red: Avoid combination	Do not coadminister: Potential for increased levels of ergotamine	Potential for increased ergotamine effects (eg, ergotism)				Contraindicated. Use alternative agents.
Atazanavir RTV 821	Red: Avoid combination	Do not coadminister: Potential for increased levels of atazanavir	Potential atazanavir-associated adverse effects (hyperbilirubinemia, GI upset, etc.)	Not studied; Potential increased atazanavir levels)			Do not coadminister ritonavir or ritonavir containing products with atazanavir / cobicistat
Atazanavir Triazolam 820	Red: Avoid combination	Do not coadminister: Potential for increased levels of triazolam	Potential for increased triazolam adverse effects (eg, increased sedation, confusion, respiratory depression)				Contraindicated. Use alternative agents.
Atazanavir SOF/VEL/VOX 819	Red: Avoid combination	Do not coadminister: Increased levels of voxilaprevir					Contraindicated. Use alternative agents.
Atazanavir Irinotecan 818	Red: Avoid combination	Do not coadminister: Increased levels of irinotecan					Contraindicated. Use alternative agents.
Atazanavir Alfuzosin 817	Red: Avoid combination	Do not coadminister: Increased levels of alfuzosin					Contraindicated. Use alternative agents.
Atazanavir Acetaminophen 816	Green: Administer standard doses	Administer standard doses		Atazanavir Cmin increased 26%	1 gram BID on days 1-20
Atazanavir Ketoconazole 815	Green: Administer standard doses	Administer standard doses		No significant change	200 mg daily on days 7-13	Not reported
Atazanavir Fluconazole 814	Green: Administer standard doses	Administer standard doses		No significant change	200 mg daily x 10 days	No significant change
Atazanavir Atenolol 813	Green: Administer standard doses	Administer standard doses		Atazanavir AUC no significant change, Cmax no significant change, Cmin decreased 26%	50 mg daily on days 7-11 and 19-23	Atenolol AUC increased 25%, Cmax increased 34%, Cmin no significant change
Atazanavir SOF/VEL 812	Green: Administer standard doses	Administer standard doses		Atazanavir Cmax increased 9%, AUC increased 20%, Cmin increased 39%.	400 mg / 100 mg	Sofosbuvir AUC increased 22%. Velpatasvir Cmax increased 55%, AUC increased 142%, Cmin increased 301%
Atazanavir DTG 811	Green: Administer standard doses	Administer standard doses		Not reported	30 mg daily	Dolutegravir AUC increased 91%, Cmax increased 50%, Cmin increased 180%
Atazanavir DTG 810	Green: Administer standard doses	Administer standard doses		Not reported	30 mg daily	Dolutegravir AUC increased 62%, Cmax increased 34%, Cmin increased 121%
Atazanavir Dabigatran 809	Green: Administer standard doses	Administer standard doses	Potential for increased risk of bleeding				No dose adjustment if CrCL < 50 ml / min. Avoid concomitant use if CrCl > 50ml / min.
Atazanavir Dabigatran 808	Green: Administer standard doses	Administer standard doses	Potential for increased risk of bleeding				No dose adjustment if CrCL < 50 ml / min. Avoid concomitant use if CrCl > 50ml / min.
Atazanavir Rosiglitazone 807	Green: Administer standard doses	Administer standard doses	Potential for increased rosiglitazone adverse effects		4 mg x 1	Rosiglitazone AUC increased 35%	Monitor for anti-diabetic agent efficacy if using unboosted atazanavir, and toxicity if using unboosted atazanavir
Atazanavir Rosiglitazone 806	Green: Administer standard doses	Administer standard doses	Potential decreased glycemic control		4 mg x 1	Rosiglitazone AUC decreased 17%	Monitor for anti-diabetic agent efficacy if using unboosted atazanavir, and toxicity if using unboosted atazanavir
Atazanavir Posaconazole 805	Green: Administer standard doses	Administer standard doses	Potential for increased atazanavir adverse effects	Atazanavir AUC increased 268%, Cmax increased 155%	400 mg BID		Monitor closely for atazanavir adverse effects during coadministration
Atazanavir Posaconazole 804	Green: Administer standard doses	Administer standard doses	Potential for increased atazanavir adverse effects	Atazanavir AUC increased 146%, Cmax increased 53%	400 mg BID		Monitor closely for atazanavir adverse effects during coadministration
Atazanavir LDV/SOF 803	Green: Administer standard doses	Administer standard doses	Potentially increased ledipasvir adverse effects. Potentially increased tenofovir disoproxil fumarate adverse effects if coadministered with protease inhibitor and ledipasvir.	Atazanavir AUC increased 27%, Cmin increased 63%	90 / 400 mg	Ledipasvir AUC(tau) increased 96%, Cmax increased 68%.	If coadministering, monitor for tenofovir disoproxil fumarate toxicity if used in the regimen.
Atazanavir LDV/SOF 802	Green: Administer standard doses	Administer standard doses	Potentially increased ledipasvir adverse effects. Potentially increased tenofovir disoproxil fumarate adverse effects if coadministered with protease inhibitor and ledipasvir.	Atazanavir AUC(tau) increased 43%	90 / 400 mg	Ledipasvir AUC(tau) increased 134%, Cmax increased 75%	If coadministering, monitor for tenofovir disoproxil fumarate toxicity if used in the regimen.
Atazanavir Methadone 801	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	Potential decreased methadone effects (withdrawl, inadequate pain control, cravings)		stable dose on d 1-15	Total methadone Cmax decresed 15%	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose
Atazanavir Lamotrigine 800	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of lamotrigine	Atazanavir with ritonavir may decrease lamotrigine plasma concentrations, Atazanavir without ritonavir is most likely not clinically significant	No significant change	100 mg daily	AUC decreased 32%	No dose adjustment necessary if administering lamotrigine and atazanavir alone. If administering lamotrigine and atazanavir plus ritonovir, lamotrigine maintenance dose may need to be increased.
Atazanavir EE/NGM 799	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of hormonal contraception				Ethinyl estradiol AUC decreased 19%, Cmax decreased 16%, Cmin decreased 37% 17-deacetyl norgestimate AUC increased 85%, Cmax increased 68%, Cmin increased 102%	With ritonavir boosted atazanavir, use an oral contraceptive containing at least 35 mcg of ethinyl estradiol. Oral contraceptives containing progestins other than norethindrone or norgestimate have not been studied.
Atazanavir Famotidine 798	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir		No significant change	20 mg BID on d 11-17 (simultaneous administration with morning atazanavir / ritonavir)		Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting.
Atazanavir Famotidine 797	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir AUC no significant change, Cmax no significant change, Cmin decreased 14%(compared to 300 mg atazanavir with 100 mg ritonavir daily)	40 mg Q12H on d 11-20		Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting.
Atazanavir Famotidine 796	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir Cmin decreased 31%	40 mg daily on d 7-12		Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting.
Atazanavir Famotidine 795	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir AUC decreased 41%, Cmax decreased 47%, Cmin decreased 42%	40 mg BID on d 7-12		Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting.
Atazanavir Famotidine 794	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir AUC decreased 41%	20 mg BID on d 11-17		Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting.
Atazanavir Famotidine 793	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir AUC decreased 38%, Cmax decreased 42%, Cmin decreased 40%	40 mg Q12H	Not reported	Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting.
Atazanavir Famotidine 792	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir AUC decreased 18%, Cmax no significant change, Cmin decreased 28%	40 mg BID on d 11-20	Not reported	Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting.
Atazanavir EFV 791	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir (all values compared to atazanavir 400 mg daily) AUC decreased 21%, Cmax no significant change, Cmin decreased 59%	600 mg daily on days 7-20	Not reported	In ART-naive patients standard dose efavirenz may be used with atazanavir 400 mg boosted with ritonavir 100 mg once daily. Do not coadminister efavirenz plus ritonavir-boosted atazanavir in ART-experienced patients. Do not coadminister efavirenz with unboosted atazanavir.
Atazanavir EFV 790	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir AUC decreased 74%, Cmax decreased 59%, Cmin decreased 93%, half-life: decreased 27%	600 mg daily on days 7-20	No significant change	In ART-naive patients standard dose efavirenz may be used with atazanavir 400 mg boosted with ritonavir 100 mg once daily. Do not coadminister efavirenz plus ritonavir-boosted atazanavir in ART-experienced patients. Do not coadminister efavirenz with unboosted atazanavir.
Atazanavir EFV 789	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential for increased atazanavir adverse effects	Atazanavir AUC increased 241%, Cmax increased 124%, Cmin increased 671%, half-life: increased 79%	600 mg daily with ritonavir 200 mg on days 15-28	Not reported	In ART-naive patients standard dose efavirenz may be used with atazanavir 400 mg boosted with ritonavir 100 mg once daily. Do not coadminister efavirenz plus ritonavir-boosted atazanavir in ART-experienced patients. Do not coadminister efavirenz with unboosted atazanavir.
Atazanavir EFV 788	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential for increased atazanavir adverse effects	Atazanavir (all values compared to atazanavir 400 mg daily) AUC increased 39% , Cmax no significant change, Cmin increased 48%	600 mg daily x days 7-20	Not reported	In ART-naive patients standard dose efavirenz may be used with atazanavir 400 mg boosted with ritonavir 100 mg once daily. Do not coadminister efavirenz plus ritonavir-boosted atazanavir in ART-experienced patients. Do not coadminister efavirenz with unboosted atazanavir.
Atazanavir Rabeprazole 787	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential loss of antiretroviral efficacy				Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.
Atazanavir Pantoprazole 786	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential loss of antiretroviral efficacy				Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.
Atazanavir Lansoprazole 785	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir AUC decreased 94%, Cmax decreased 91%, half-life: no significant change	60 mg daily x 2 doses		Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.
Atazanavir Omeprazole 784	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir AUC decreased 94%, Cmax decreased 96%, Cmin decreased 95%	40 mg daily x 5 d		Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.
Atazanavir Omeprazole 783	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir AUC decreased 76%, Cmax decreased 72%, Cmin decreased 78%	40 mg daily x 10 d		Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.
Atazanavir Omeprazole 782	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir AUC decreased 70%, Cmax decreased 66%, Cmin decreased 76%	40 mg daily x 10 d		Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.
Atazanavir Omeprazole 781	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir AUC decreased 61%, Cmax decreased 56%, Cmin decreased 66%	40 mg daily x 10 d		Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.
Atazanavir Omeprazole 780	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir AUC decreased 42%, Cmax decreased 39%, Cmin decreased 46%	20 mg daily on d 17-23		Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.
Atazanavir Omeprazole 779	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir AUC decreased 30%, Cmin decreased 31%, Cmax decreased 31%	20 mg daily on d 17-23		Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.
Atazanavir Omeprazole 778	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Increased omeprazole effects	Not reported	40 mg x 1 on d 7 and 20	Omeprazole AUC increased 45%, Cmax increased 24%	Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.
Atazanavir Esomeprazole 777	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential loss of antiretroviral efficacy				Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir if boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.
Atazanavir Pantoprazole 776	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir					Administer proton pump inhibitor at least 12 hours before atazanavir / cobicistat. Proton pump inhibitors should not exceed a dose equivalent to omeprazole 20 mg daily in protease inhibitor naive patients. Proton pump inhibitors are not recommended in protease inhibitor experienced patients.
Atazanavir TDF 775	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential loss of antiretroviral efficacy with lower atazanavir concentrationss. Potential for increased tenofovir adverse effects	Atazanavir Cmax decreased 28%, AUC decreased 25%, Cmin decreased 26%, Ritonavir Cmax decreased 28%, AUC decreased 25%, Cmin no significant change	300 mg daily on days 15-42	Not reported	Administer 300 mg atazanavir with 100 mg ritonavir when used as part of a tenofovir containing regimen. Do not coadminister TDF with unboosted atazanavir (400 mg).
Atazanavir Cimetidine 774	Yellow: Adjust dosing	Adjust dosing to avoid reduced atazanavir levels	Potential loss of antiviral efficacy				Unboosted atazanavir 400 mg: give atazanavir 2 hrs before or 10 hours after H2-blocker. Single doses of H2-blockers should not exceed 20 mg of famotidine (or equivalent). Additionally, if treatment naive, total daily dose of H2 blocker should not exceed 40 mg of famotidine (or equivalent). Atazanavir 300 mg boosted with ritonavir or cobicistat: Give boosted atazanavir at same time as H2 blocker or 10 hours or more after. Total doses of H2 blocker should not exceed the equivalent of 40 mg BID famotidine (treatment naive) or 20 mg BID for (treatment experienced patients). If using tenofovir disoproxil fumarate, atazanavir, and H2 blocker in treatment experienced patient, increase atazanavir dose to 400 mg in addition to boosting with ritonavir or cobicistat.
Atazanavir Bosentan 773	Yellow: Adjust dosing	Adjust dosing to avoid reduced atazanavir levels	Potential decreased antiviral effects of atazanavir				Do not coadminister bosentan with unboosted atazanavir, For patients receiving atazanavir plus ritonavir for >10 days, start bosentan at 62.5mg daily or every other day based on individual tolerability, Discontinue bosentan at least 36 hours before starting atazanavir / ritonavir. At least 10 days after starting atazanavir / ritonavir, resume bosentan at 62.5mg daily or every other day based on individual tolerability.
Atazanavir Aluminum and magnesium hydroxide antacid 772	Yellow: Adjust dosing	Adjust dosing to avoid reduced atazanavir levels					Separate administration of atazanavir / cobicistat and antacids by a minimum of 2 hours.
Atazanavir Tadalafil 771	Yellow: Adjust dosing	Adjust dosing to avoid increased tadalafil levels	Potentially increased tadalafill effects (eg, hypotension, priapism)				For erectile dysfunction initiate tadalafil 5 mg dose and do not exceed 10 mg every 72 hours. Monitor adverse effects. For patients taking a protease inhibitor (stable > 7 days) requiring tadalafil for pulmonary arterial hypertension initiate 20 mg once daily and increase to 40 mg once daily based on tolerability. Patients currently on tadalafil who require a PI should stop tadalafil ³24 hours before PI initiation, take the PI for 7 days, then resume tadalafil at 20 mg. Maximum recommended daily dose for treatment of BPH is 2.5 mg daily.
Atazanavir Sildenafil 770	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of sildenafil. (Do not coadminister for pulmonary hypertension)	Potentially increased sildenafil effects (eg, hypotension, priapism)				For erectile dysfunction, initiate sildenafil (Viagra) 25 mg every 48 hours and monitor for adverse effects. Do not coadminister if using sildenafil for pulmonary arterial hypertension.
Atazanavir Rosuvastatin 769	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of rosuvastatin	Potential for increased rosuvastatin adverse effects (e.g. myopathy)		10 mg daily	Rosuvastatin AUC increased 213%, Cmax increased 600%	Initiate lowest dose and titrate carefully. Do not exceed 10mg rosuvastatin daily.

Subscribe to Atazanavir